Abstract:Following the publication of the above article, an interested reader drew to the authors' attention that, with the 'Adjacent' row (top row) of immunohistochemical images shown in Fig. 2 on p. 646, the fourth and fifth panels along (the 'RAB11A' and 'RAB9A' data panels) contained an overlapping section of data, such that data which were intended to show the results from differently performed experiments had apparently been derived from the same original source. After consulting their original data, the authors were able to determine that the duplication of these panels had inadvertently occurred during the process of compiling Fig. 2. The revised version of Fig. 2, featuring the correct data for the 'Adjacent/RAB9A' experiment, is shown below. The authors confirm that the error associated with this figure did not have any significant impact on either the results or the conclusions reported in this study, and are grateful to the Editor of International Journal of Molecular Medicine for allowing them the opportunity to publish this Corrigendum. Furthermore, they apologize to the readership of the Journal for any inconvenience caused. [International Journal of Molecular Medicine 44: 643‑651, 2019; DOI: 10.3892/ijmm.2019.4213].

Correction To: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells: the Effect of Combining RNA Interference with Tyrosine Kinase Inhibitors or Cetuximab

Targeting The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Cells: The Effect Of Combining Rna Interference With Tyrosine Kinase Inhibitors Or Cetuximab (Vol 10, 28, 2012)

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Erratum: Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

[Corrigendum] Inhibition of sphingosine-1-phosphate phosphatase 1 promotes cancer cells migration in gastric cancer: Clinical implications.

ERRATUM: GH modulates hepatic epidermal growth factor signaling in the mouse

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Corrigendum to "Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients"

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)

Correction: Loss of EGFR Signaling-Regulated Mir-203 Promotes Prostate Cancer Bone Metastasis and Tyrosine Kinase Inhibitors Resistance

Correction: YAP Suppresses Lung Squamous Cell Carcinoma Progression Via Deregulation of the DNp63–GPX2 Axis and ROS Accumulation

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

[Corrigendum] Effects of miR‑340 overexpression and knockdown on the proliferation and metastasis of NSCLC cell lines

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Corrigendum to ‘silencing KIF18B Enhances Radiosensitivity: Identification of a Promising Therapeutic Target in Sarcoma’ [ebiomedicine 61 (2020) 103,056]

Correction for Lin Et Al., “Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes the Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Via Metastatic Tumor Antigen 1 and Mechanistic Target of Rapamycin Signaling Induction”

Erratum: Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.

Correction: Overexpression of Wildtype EGFR is Tumorigenic and Denotes a Therapeutic Target in Non-Small Cell Lung Cancer